Colistin in ventilator-associated pneumonia

Clinical Infectious Diseases

Volumn 54, Issue 5, 2012, Pages 681-683

  Falagas, M E ^a,b,c   Rafailidis, Petros I ^a,b  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; COLISTIN; EXTENDED SPECTRUM BETA LACTAMASE;

ACINETOBACTER BAUMANNII; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NOTE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; COLISTIN; HUMANS; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 84856924703     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir931     Document Type: Note

References (19)

1. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40:1333-41.
2. Florescu DF, Qiu F, McCartan MA, Mindru C, Kalil AC. What is the efficacy and safety of colistin for the treatment of ventilatorassociated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2011; 54:670-80.
3. Hachem RY, Chemaly RF, Ahmar CA, et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 2007; 51: 1905-11.
4. Falagas ME, Sideri G, Vouloumanou EK, Papadatos JH, Kafetzis DA. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J 2009; 28:123-7.
5. Falagas ME, Rafailidis PI. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit Care 2007; 11:134.
6. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drugresistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2011; doi: 10.1111/j. 1469-0691.2011.03570.x.
7. Marchaim D, Gottesman T, Schwartz O, et al. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2010; 54: 5099-104.
8. Schwaber MJ, Lev B, Israeli A, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011; 52:848-55.
9. Borer A, Saidel-Odes L, Riesenberg K, et al. Attributable mortality rate for carbapenemresistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009; 30: 972-6.
10. Falagas ME, Kouranos VD, Michalopoulos A, Rodopoulou SP, Athanasoulia AP, Karageorgopoulos DE. Inadequate statistical power of published comparative cohort studies on ventilator-associated pneumonia to detect mortality differences. Clin Infect Dis 2010; 50:468-72.
11. Kwa AL, Falagas ME, Michalopoulos A, Tam VH. Benefits of aerosolized colistin for ventilator-associated pneumonia: absence of proof versus proof of absence? Clin Infect Dis 2011; 52:1278-9, author reply 1279-80.
12. Agrafiotis M, Siempos II, Ntaidou TK, Falagas ME. Attributable mortality of ventilator-associated pneumonia: a metaanalysis. Int J Tuberc Lung Dis 2011; 15: 1154-63.
13. Ferreira F, Vincent JL, Brun-Buisson C, Sprung C, Sibbald W, Cook D. Doctors' perceptions of the effects of interventions tested in prospective, randomised, controlled, clinical trials: results of a survey of ICU physicians. Intensive Care Med 2001; 27: 548-54.
14. Falagas ME, Rafailidis PI. Nephrotoxicity of colistin: new insight into an old antibiotic. Clin Infect Dis 2009; 48:1729-31.
15. Matthaiou DK, Michalopoulos A, Rafailidis PI, et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 2008; 36:807-11.
16. Bergen PJ, Li J, Nation RL. Dosing of colistinback to basic PK/PD. Curr Opin Pharmacol 2011; 11:464-9.
17. Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010; 35:194-9.
18. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-94.
19. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of gramnegative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011; 66:2070-4.